DBV Technologies SA – (DBVT) Given Consensus Recommendation of “Hold” by Brokerages

DBV Technologies SA – (NASDAQ:DBVT) has received a consensus rating of “Hold” from the thirteen research firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $48.83.

Several brokerages have recently weighed in on DBVT. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of DBV Technologies in a research note on Monday, October 23rd. Morgan Stanley cut shares of DBV Technologies from an “overweight” rating to an “equal weight” rating in a research note on Monday, October 23rd. Leerink Swann set a $49.00 price target on shares of DBV Technologies and gave the stock an “outperform” rating in a research note on Monday, October 23rd. Barclays decreased their price target on shares of DBV Technologies from $58.00 to $30.00 and set an “overweight” rating for the company in a research note on Monday, October 23rd. Finally, Deutsche Bank raised their target price on shares of DBV Technologies from $46.00 to $56.00 in a research note on Sunday, October 8th.

Several large investors have recently added to or reduced their stakes in DBVT. Airain ltd bought a new position in shares of DBV Technologies in the second quarter valued at $333,000. Sectoral Asset Management Inc grew its stake in shares of DBV Technologies by 34.2% in the second quarter. Sectoral Asset Management Inc now owns 179,152 shares of the company’s stock valued at $6,398,000 after buying an additional 45,653 shares in the last quarter. Janus Henderson Group PLC bought a new position in shares of DBV Technologies in the second quarter valued at $90,724,000. Dynamic Technology Lab Private Ltd bought a new position in shares of DBV Technologies in the second quarter valued at $222,000. Finally, Sabby Management LLC bought a new position in DBV Technologies during the second quarter worth $1,339,000. 46.92% of the stock is owned by institutional investors and hedge funds.

DBV Technologies (NASDAQ:DBVT) opened at $24.60 on Tuesday. The firm has a market cap of $1,210.00, a P/E ratio of -4.98 and a beta of 1.21. DBV Technologies has a 52 week low of $20.58 and a 52 week high of $50.57.

WARNING: “DBV Technologies SA – (DBVT) Given Consensus Recommendation of “Hold” by Brokerages” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2018/01/02/dbv-technologies-sa-dbvt-given-consensus-recommendation-of-hold-by-brokerages.html.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply